HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiotherapy associated with improved survival for high-grade sarcoma of the extremity.

AbstractBACKGROUND:
The impact of radiotherapy on local control in limb-preserving surgery for high-risk sarcoma has been well studied. However, the impact of the use and timing of radiation therapy on survival is unclear.
METHODS:
From 1988 to 2010, patients with Stage III extremity sarcoma were identified within the SEER registry and cohorts were created using propensity score matching between irradiated and non-irradiated groups.
RESULTS:
A total of 2,606 patients were identified, with a median age of 59 years a majority were white (81%), male (54%), received radiotherapy (78%), and had lower extremity (80%) sarcomas. The most common subtype was fibrohistiocytic (29.8%). Patients treated with radiotherapy were younger (57.2 vs. 60.3 years) and differed in subtype compared to those untreated. The matched cohorts were better balanced for all factors. Radiation therapy was associated with a 5% 5-year survival advantage on univariate analysis for both the unmatched (P = 0.002) and matched cohorts (P = 0.01). On multivariate analysis radiotherapy was associated with a 20% and 30% survival advantage for the matched and unmatched cohorts, respectively (P ≤ 0.02). The timing of radiotherapy did not affect survival.
CONCLUSIONS:
Radiotherapy, regardless of the timing, is associated with improved survival in high-risk sarcoma.
AuthorsSwapnil D Kachare, Jason Brinkley, Nasreen A Vohra, Emmanuel E Zervos, Jan H Wong, Timothy L Fitzgerald
JournalJournal of surgical oncology (J Surg Oncol) Vol. 112 Issue 4 Pg. 338-43 (Sep 2015) ISSN: 1096-9098 [Electronic] United States
PMID26250782 (Publication Type: Journal Article)
Copyright© 2015 Wiley Periodicals, Inc.
Topics
  • Extremities (radiation effects)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Grading
  • Prognosis
  • Propensity Score
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • SEER Program
  • Sarcoma (mortality, pathology, radiotherapy)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: